iScience (May 2022)

Synthetic lethality-based prediction of anti-SARS-CoV-2 targets

  • Lipika R. Pal,
  • Kuoyuan Cheng,
  • Nishanth Ulhas Nair,
  • Laura Martin-Sancho,
  • Sanju Sinha,
  • Yuan Pu,
  • Laura Riva,
  • Xin Yin,
  • Fiorella Schischlik,
  • Joo Sang Lee,
  • Sumit K. Chanda,
  • Eytan Ruppin

Journal volume & issue
Vol. 25, no. 5
p. 104311

Abstract

Read online

Summary: Novel strategies are needed to identify drug targets and treatments for the COVID-19 pandemic. The altered gene expression of virus-infected host cells provides an opportunity to specifically inhibit viral propagation via targeting the synthetic lethal and synthetic dosage lethal (SL/SDL) partners of such altered host genes. Pursuing this disparate antiviral strategy, here we comprehensively analyzed multiple in vitro and in vivo bulk and single-cell RNA-sequencing datasets of SARS-CoV-2 infection to predict clinically relevant candidate antiviral targets that are SL/SDL with altered host genes. The predicted SL/SDL-based targets are highly enriched for infected cell inhibiting genes reported in four SARS-CoV-2 CRISPR-Cas9 genome-wide genetic screens. We further selected a focused subset of 26 genes that we experimentally tested in a targeted siRNA screen using human Caco-2 cells. Notably, as predicted, knocking down these targets reduced viral replication and cell viability only under the infected condition without harming noninfected healthy cells.

Keywords